BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsUpgradesPrice Target
BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.
BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.